Can-Fite BioPharma Ltd. (CANF) AI Stock Analysis

Can-Fite BioPharma Ltd., based in Petah Tikva, Israel, is a clinical-stage biopharmaceutical company focused on small molecule treatments for cancer, liver inflammatory diseases, and erectile dysfunction. Its lead candidate, Piclidenoson, has completed Phase III trials for psoriasis and Phase II trials for COVID-19. Namodenoson is advancing through Phase III trials for hepatocellular carcinoma and Phase IIb trials for non-alcoholic steatohepatitis, while CF602 is in pre-clinical trials for erectile dysfunction. Can-Fite also researches predictive biomarker blood tests for the A3AR receptor and maintains collaboration agreements with CMS Medical and Univo Pharmaceuticals.

Can-Fite generated $853,000 in revenue in FY2021 before experiencing annual declines to $810,000 in FY2022, $743,000 in FY2023, $674,000 in FY2024, and $408,212 in FY2025, representing a 5-year revenue CAGR of -11.8%. Revenue growth fell 39.4% in FY2025, while gross margin decreased from 100.0% in FY2024 to 94.1%. Net loss for FY2025 was -$9.9M, accompanied by an operating margin of -2456.8% and R&D expense of $6.7M. Over the trailing twelve months ending June 30, 2026, revenue stood at $405,000 with EPS of -$13.23 and an operating margin of -2316.8%.

As of June 30, 2026, Can-Fite held $7.0M in cash and short-term investments against $49,000 in total debt, resulting in net cash of $7.0M and a debt-to-equity ratio of 0.01. Shareholders' equity was $4.9M and total assets stood at $8.1M, supporting a current ratio of 3.60. For FY2025, operating cash flow and free cash flow both registered at -$9.0M, with capital expenditures of $2,018. Over the last five years, Can-Fite's share count declined 98.9%.

Can-Fite trades at a forward P/E of 3.0x, below the 17.3x median of its US-listed Healthcare peers. Its price-to-sales multiple is 13.2x compared to the peer median of 4.1x, while its EV/EBITDA is 0.1x against the peer median of 12.0x. The company holds an enterprise value of -$2.2M and a market capitalization of $5.3M. Over the past year, the stock fell 83.7% compared to a 16.8% gain for the S&P 500, and its 5-year return sits at -99.4% versus 83.0% for the index.

Can-Fite has 2 Strong Buy ratings and no Buy, Hold, Sell, or Strong Sell ratings. The mean price target is $8.00, which is 354.5% above the last close of $1.76. For the current fiscal year ending December 31, 2026, consensus estimates project revenue of $404,000 and EPS of -$2.04, reflecting EPS growth of 83.5%. For the next fiscal year, 1 analyst projects revenue of $404,000 and an EPS of -$0.91. Over the last 4 quarters, the company delivered 3 EPS beats.

This page is an AI-written research summary of Can-Fite BioPharma Ltd. (CANF). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: CANF income statement, CANF balance sheet, CANF key metrics, CANF analyst forecast, CANF chart. See the CANF stock overview for the latest quote and news.